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Abstract
Objective—To predict the likelihood of hospital-onset Clostridium difficile infection (HO-CDI) 
based on patient clinical presentations at admission
Design—Retrospective data analysis
Setting—Six US acute care hospitals
Patients—Adult inpatients
Methods—We used clinical data present at the time of admission in electronic health record 
(EHR) systems to develop and validate a HO-CDI predictive model. The outcome measure was 
HO-CDI cases identified by a non-duplicate positive C. difficile toxin assay result with stool 
specimens collected >48 hours after inpatient admission. We fit a logistic regression model to 
predict the risk of HO-CDI. We validated the model using 1,000 bootstrap simulations.
Results—Among 78,080 adult admissions, 323 HO-CDI cases were identified (4.1/1,000 
admissions). The logistic regression model yielded 14 independent predictors, including hospital 
community onset CDI pressure, patient age ≥65, previous healthcare exposures, CDI in previous 
admission, admission to the intensive care unit, albumin ≤3 g/dL, creatinine >2.0 mg/dL, bands > 
32%, platelets ≤150 or >420 109/L, and WBC >11,000 mm3. The model had a c-statistic of 0.78 
(95% CI: 0.76, 0.81) with good calibration. For 79% patients with risk score of 0-7, there were 19 
HO-CDIs per 10,000 admissions; for patients with risk score of 20+, there were 623 HO-CDIs per 
10, 000 admissions (P<0.0001).
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Conclusion—Using clinical parameters available at the time of admission, this HO-CDI model 
displayed a good predictive ability. It may have utility as an early risk identification tool for HO-
CDI preventive interventions and outcome comparisons.
Keywords
Clostridium difficile Infection (CDI); predictive model; CDI risk score; electronic health record 
(EHR); electronic medical record (EMR); laboratory data; risk adjustment
Clostridium difficile infections (CDI) are one of the most frequent healthcare associated 
infections (HAI) in the USA,1 having more than doubled in prevalence in U.S. hospitals 
from 2000 to 2009.2 Meanwhile, the US National Vital Statistics suggest that deaths due to 
CDI have increased nearly 10-fold from 1999 to 2010, becoming the 18th leading cause of 
death for people aged 65 and older in 2010.3 In addition, there is a major economic burden 
from CDI.4,5
Several studies have investigated the risk for developing CDI based on various combinations 
of patient, treatment, and environmental factors either already present at the time of hospital 
admission or occurring after admission.6 Factors that reflect ongoing modification in host 
susceptibility to CDI, such as antibiotic use, and factors that reflect ongoing risk of 
transmission, such as Clostridium difficile–associated disease (CDAD) pressure, may be 
followed throughout the entire hospital stay and, as such, may be considered as care process 
variables that are at least partially under the control of providers and the hospital. Such risk 
predictive models that incorporate both patient and care process risks throughout the hospital 
stay can be useful for internal hospital quality improvement purposes. On the other hand, 
there are advantages to a risk score system that restricts candidate variables to those brought 
in by patients when they are admitted to an acute care setting.
One use of on-admission risk stratification of individual patients is to assist hospitals in 
directing more specific, costly, or difficult to implement prevention strategies (e.g. 
probiotics, passive immunization, or more stringent avoidance of high-risk antibiotics) to 
those identified as high risk patients. Another use of an on-admission risk score is to adjust 
rates of hospital-onset (HO)-CDI by underlying patient risks that are beyond the control of 
hospitals, thereby advancing more fair inter-hospital comparisons. The objective of our 
study was to devise a HO-CDI risk predictive model using patient data available at the time 
of acute care admission only.
METHODS
Data Source
We analyzed clinical data in a Clinical Research Database from CareFusion (CareFusion 
Inc., San Diego, CA, USA). This data set consisted of electronically captured daily census, 
location, clinical, and microbiology data (e.g., specimen collection date/time, location, and 
test results), general laboratory test results, demographics, admission sources, and other 
clinical and administrative data from CareFusion’s electronic HAI surveillance system 
MedMined® and its former MediQual® research database, which have been previously 
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described elsewhere5,7,8, 9 The data set used for this study was a deidentified limited data 
set. The study protocols were approved by the New England IRB (Wellesley, MA).
Study Cohort
Adult patients (age 18 or older) discharged from 6 acute care hospitals between January 1, 
2007 and June 30, 2008.
Definition of HO-CDI
We defined HO-CDI among adult (≥18 years) inpatients as a non-duplicate positive C. 
difficile stool diagnostic assay (EIA toxin assay A&B) collected >48 hours after inpatient 
admission. For practical purposes, non-duplicate CDI was defined as no prior positive results 
within 14 days per definition of the Centers for Disease Control and Prevention (CDC).10 
Non-recurrent CDI cases were defined as a positive result after more than eight weeks 
without another positive. Recurrent CDI cases were identified as the second positive result 
between 2 and 8 weeks following any previous positive result.5,8 If a patient had more than 
one HO-CDI incidences in a single admission, it was counted only once in the model fit 
process because the analytic unit was hospital admission.
Candidate Predictor Variables
Candidate predictor variables included patients’ intrinsic risk that decreased the immune 
function, increased risk of C. difficile colorization, and exposure to antibiotics use: 1) 
demographics (age, gender); 2) previous healthcare exposure (admitted from another acute 
care hospital, a skilled nursing facility, and discharge from the same hospital within 30 
days); 3) CDI during previous hospital stay; 4) potential infections in the current or previous 
hospitalization (identified with Nosocomial Infection Marker [NIM®] or Community 
Infection Marker [CIM®] status. A NIM or CIM is defined as a positive microbiologic 
specimen with a non-duplicate hospital isolate, where the specimen is collected from a 
single source. This algorithm-based system accounts for timing of specimen collection in 
relation to patient admission and location. It excludes common contaminations. For NIM, 
the specimen is collected three days after admission. For CIM, the specimen is collected 
within three days from admission);7 5) need for intensive care (admission to an intensive 
care unit (ICU), need for mechanical ventilation); and 6) admission laboratory testing results 
within 24 hours (serum chemistry, blood gas, cardiac markers, hematology, and coagulation 
parameters) as additional indicators of clinical severity. For continuous laboratory variables, 
we used previously published cuts for the categorization.9,11,12 Patients who did not have a 
particular laboratory measure on admission were treated as not clinically indicated and 
hence, would be in the reference group.
Previous studies found that CO-CDI pressure was associated with increased risk of HO-
CDI.6,8 It is one of the hospital-level risk factors adjusted by the CDC National Healthcare 
Safety Network.13 Hence, in addition to the individual’s potential intrinsic risk as measured 
by the above clinical presentation, we also devised two community onset (CO) CDI pressure 
variables, defined a priori, to represent the environmental risk. (1) CO-CDI Pressure: rolling 
average number of CO-CDI 14 days prior to and 3 days after the patient’s index admission 
divided by the total number of hospital admissions during this period. The CO-CDI Pressure 
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only accounted for CO-CDIs in patients who did not have previous discharge from the same 
hospitals within 12 weeks. (2) All CO-CDI Pressure: this variable counts for all CO-CDIs, 
including those patients who were discharged from the same hospitals within 12 weeks. We 
evaluated the distribution of the CDI pressure in relation to the CDI rate and determined the 
cutpoint for categorizing this variable to simplify the model application.
Development and Validation of Predictive Model
We conducted univariable analysis of candidate variables. Variables with significant 
association to HO-CDI (P<0.05) were included in the multivariable logistic regression 
analysis. We also tested model using a P-value <0.10 for eligible candidate variable. We fit 
the logistic regression model using the step-wise approach. We also tested backwards section 
approach. We reiterated the model fitting process and reviewed models among authors, 
including a CDI expert, a gastroenterologist, an intensivist, and two biostatisticians. We 
combined multiple levels of certain general laboratory data to create a more robust estimate 
in the model when the coefficients were similar and the numbers were small. The final 
model was determined by clinical plausibility and statistical significance.14,15 We used a P-
value of <0.05 as a general criterion for model variable retention, but also forced in certain 
variables with a P-value nearly significant for the final model based on theoretical 
importance. We converted the model coefficients into a risk score system. Specifically, we 
divided each variable coefficient by the smallest coefficient in the model and rounded this 
ratio to the nearest integer.16 We summed up all pertinent variable points for each patient 
into an aggregated HO-CDI risk score. We then validated this risk model by conducting 
1,000 bootstrap simulations.17 The bootstrap process randomly samples with replacement 
the study cohort. It fits the model and generates the c-statistic for each random sample. We 
used the 2.5th and 97.5th percentiles as the lower and upper limits of c-statistic 95% 
confidence intervals from the 1,000 simulations.
To simplify the clinical application, we devised a risk score grouping that approximated a 
linear relationship between the HO-CDI risk and the HO-CDI rates by varying the cut points 
of the groups.
RESULTS
Patient Characteristics
Among 78,080 adult admissions, 323 HO-CDI cases (including 310 non-recurrent and 13 
recurrent CDIs) were identified (4.1/1,000 admissions) (Table 1). Patients with HO-CDI 
were older, more likely to have previous healthcare exposures, to be admitted to the ICU, 
and more likely to have abnormal laboratory test results on admission.
HO-CDI Model
The logistic regression model yielded 14 independent predictors (Table 2). Risk factors 
included CO-CDI Pressure greater than 60th percentile, age >64, transferred from another 
hospital or skilled nursing facilities, CDI during previous hospital stay, previous hospital 
discharge within 30 days, admission to the intensive care unit, albumin ≤3 g/dL, creatinine 
>2.0 mg/dL, bands >32%, platelets ≤150 or >420 10^9/L, and white blood cell counts 
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>11,000mm3. The model had a c-statistic of 0.78 (95% CI: 0.76, 0.81) (Figure 1). The 
Hosmer-Lemeshow χ2 was12.6 (P=0.13), indicating goodness of fit (Figure 2).
The model that incorporated the All CO-CDI Pressure yielded a slighted greater measure of 
association than the model using the CO-CDI pressure based only on those patients not 
recently discharged from the measurement hospital. The remaining variables displayed 
similar estimates. The model c-statistic was 0.79 and the Hosmer-Lemeshow χ2 was15.8 
(P=0.03).
The risk score ranged from 0 to 28, with a median of 4 and interquartile range of 2 and 7 for 
the model with CO-CDI pressure variable. The risk score distribution and corresponding 
admission volume were in Figure 3. The linearization of the risk score resulted in a nearly 
linear relationship of increased scores and higher observed HO-CDI rates (Figure 4). The 
Cochran-Armitage trending test was significant (P<0.0001). For patients with risk score of 
0-7, the observed HO-CDI attack rate during hospital stay was 19/10,000 admissions. In 
contrast, for patients with a risk score of 20 or higher, the observed HO-CDI attack rate was 
623/10,000 admissions. Approximately 79% of all admissions had a HO-CDI risk score of 7 
or less. They accounted for 35% of all HO-CDI cases. Patients with a HO-CDI score 8 or 
more accounted for 21% of all admissions but 65% of all HO-CDI cases.
DISCUSSION
We have developed a risk stratification score based upon parameters available at the time of 
admission. We found that the 21% patients within the higher risk strata accounted for 65% 
of all HO-CDI cases. While validation of this scoring system should be performed in other 
hospitalized patient populations, preferably in settings with available electronic health data 
to allow automation, this scoring system could be an important tool for prioritizing more 
specialized, resource-intensive prevention strategies. If aggregated across a facility, it could 
also function as a risk adjustment tool for HO-CDI rates to allow inter-hospital comparisons 
that better reflect the effectiveness of intra-hospital prevention efforts.
The principal epidemiologic risk factors for CDI arise from antibiotic exposure, which 
perturbs the lower intestinal microbiota impairing an important host defense mechanism, and 
factors that reflect the likelihood of acquiring C. difficile such as admission to a ward with a 
high colonization pressure.6 There are also other risk factors such as age and underlying 
illness that may be markers of decreased immunocompetence. Among the 14 factors in our 
risk scoring system, several may be surrogates for both increased transmission risk and 
likely exposure to antibiotics. For example, both admission to an ICU and mechanical 
ventilation may serve as dual surrogates. The ICU is a location of increased exposure to 
antibiotics as well as to other patients who are either colonized or infected with C. difficile; 
mechanical ventilation is an additional marker of disease severity that increases likely 
exposure to antibiotics and is associated with longer ICU stays.
The incubation period of C. difficile (i.e., the period between the most recent exposure and 
symptomatic infection) is generally thought to be less than a week and, except for those 
patients previously symptomatic with CDI (who are at risk for recurrence), patients who 
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remain asymptomatically colonized for a prolonged period with C. difficile are thought to be 
at paradoxically decreased, rather than increased, risk for developing symptomatic 
infection.18 This is thought due to a boosting of anti-toxin antibodies in such 
asymptomatically colonized patients. Because of this phenomenon, it appears most likely 
that the association of HO-CDI with previous healthcare exposures in our model (i.e. 
previous admission, transfer from a nursing home or outside hospital), independent of 
previous CDI, reflect preceding antibiotic exposures. Metagenomic studies of the lower 
intestinal microbiota demonstrate dysbiosis that persists for up to 6 months after relatively 
short single antibiotic exposures; repeated or more intense exposure lead to even more 
severe and persistent dysbiosis.19 Meanwhile, epidemiologic studies suggest the risk for CDI 
increases 7-10 fold while patients are on antibiotics and in the month following cessation, 
and that the risk remains elevated 2-3 fold in the two months after that.20
Predicting the likelihood of HO-CDI at the time of admission may help clinicians to devise 
early preventative strategies. Although application of our risk score needs to be tested 
prospectively, preferably in hospitals with advanced electronic health records, restricting 
data requirements to patient risk factors at the time of admission simplifies risk score 
application. Incorporation of environmental risk factors, such as the risk of exposure to C. 
difficile during the entire hospital stay, would be more complex and challenging in terms of 
implementation, especially across institutions. Nonetheless, development of such a dynamic 
risk index, even to the point of daily calculation of CDI risk, could be an important future 
demonstration of how an advanced electronic health record contributes to risk reduction.
Dubberke, et al. showed that “CDAD pressure”, measured as each patient’s total exposure to 
infectious CDI patients divided by the patient’s length of stay at risk for CDI, was the most 
predictive factor for HO-CDI with an odds ratio of 13.6 We restricted the CDI pressure to 
community-onset only which is more suitable for aggregating patient risk at the facility-level 
so as to assist with inter-hospital comparisons; CO-CDI unrelated to a previous 
hospitalization is outside the control of a given hospital and therefore is more appropriately 
included in facility-level risk adjustment. In the future, if a more dynamic CDI patient-
focused risk model were developed that accounted for daily intra-hospital exposures, it could 
incorporate the HO-CDI rate on a given patient ward so as to more precisely predict daily 
transmission risk. However, including the HO-CDI rate would render the model no longer 
appropriate for risk adjustment at the facility level as hospital-onset infections reflect, in 
addition to a facilities baseline risk, the degree to which intra-hospital prevention strategies 
have been successfully implemented.
In addition to factors that serve as surrogates for either antibiotic exposure or exposure to 
patients who are colonized or infected with C. difficile, our model included several factors 
that reflect an increased intrinsic patient risk for infection following colonization. Given the 
aforementioned importance of humoral immunity as a host defense, this intrinsic infection 
risk is likely mediated via compromising host immune-responsiveness. Previous studies have 
found that advanced age, hypoalbuminemia, and an elevated creatinine were associated with 
HO-CDI.6 Meanwhile, abnormal platelets, elevated bands, and white blood cell counts may 
reflect underlying infections at other body sites that increase the likelihood of the patient 
becoming exposed to antibiotics.
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Limitations
Our study has limitations. First, although we used data from multiple sites, which is an 
improvement over a single center study in terms of diversity of patients, the number of 
hospitals and number of HO-CDI cases were still relatively small. The small number of 
hospitals may not represent the diversity of nationwide CO-CDI pressure. This may partially 
explain the relatively small impact of this variable in the model. More representative data are 
needed to further validate the HO-CDI risk score. Second, application of the HO-CDI risk 
score needs to be tested in a prospective setting, preferably in automated electronic medical 
record environment. Third, our risk score restricted data use to electronically captured data 
that are widely available, such as microbial results, general laboratory test results, previous 
hospitalization status, and source of admissions. Future studies may test additional 
predictive ability when more patient clinical data at admission, such as vital signs, become 
more readily available through electronic automation process. Fourth, the database didn’t 
have outpatient information regarding antibiotic use prior to admission, a known risk for C. 
difficile. We opted to identify surrogates of potential antibiotic exposure, such as clinical 
severity, ICU admissions, exposure to healthcare prior to admission, and infection markers, 
which were found to be significant risk factors. Finally, for use as a risk identification tool, 
both the number of patients needed to screen, and, based upon the estimated prevention 
efficacy of an intervention, the number needed to treat with an intervention to prevent one 
case of HO-CDI, will be required to determine the overall cost effectiveness of the tool.
CONCLUSIONS
Using patient clinical parameters available at the time of admission, this HO-CDI model 
displays a good predictive ability. Although further analyses will be required to determine its 
feasibility and cost effectiveness, it may have utility as a real-time early risk identification 
tool for HO-CDI preventive interventions. Once aggregated across a facility, it could also 
function to improve risk adjustment for inter-facility comparisons.
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Figure 1. 
Receiver Operating Curve for HO-CDI Risk Score Models. Model with CO-CDI Pressure 
had a c-statistic of 0.78. Model with All-CO-CDI Pressure had a c-statistic of 0.79.
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Figure 2. 
Hosmer-Lemeshow Calibration
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Figure 3. 
Distribution of HO-CDI Risk Score and Corresponding Admission Volume. *Score 20 and 
above were collapsed because of small numbers. **Model with CO-CDI Pressure was 
presented. Model with All-CO-CDI Pressure yielded similar distribution. Data were not 
shown.
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Figure 4. 
Linearization of HO-CDI Risk and Corresponding Proportion of Admission. * Model with 
CO-CDI Pressure was presented. Model with All-CO-CDI Pressure yielded similar 
distribution. Data were not shown.
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Table 1
Patient Characteristics
Variable Non-Cases, n (Column %)
HO-CDI Cases, n 
(Column %) Univariate P-Value
Total n 77,757 323
Demographics
Age <65 35,331 (45.4) 84 (26.0)
<0.000165-84 32,776 (42.2) 187 (57.9)
>84 9,650 (12.4) 52 (16.1)
Female 42,225 (54.3) 173 (53.6)
0.789
Male 35,532 (45.7) 150 (46.4)
Medicaid 4,695 (6.0) 15 (4.6)
0.0004Medicare 29,201 (37.6) 156 (48.3)
Other payers 43,861 (56.4) 152 (47.1)
Previous Healthcare Exposure
Transferred from other acute care hospital 4,057 (5.2) 35 (10.8) <0.0001
Transferred from skilled nursing facilities 1,919 (2.5) 42 (13.0) <0.0001
Same hospital discharge during previous 30 days 9,916 (12.8) 94 (29.1) <0.0001
CDI during previous hospitalization 306 (0.4) 10 (3.1) <0.0001
NIM in previous hospitalization 1,144 (1.5) 11 (3.4) 0.0041
CIM in previous hospitalization 3,174 (4.1) 29 (9.0) <0.0001
Clinical Presentation at Admission
Admitted to intensive care unit 12,452 (16.0) 115 (35.6) <0.0001
Mechanic ventilation on admission 2,268 (2.9) 52 (16.1) <0.0001
CIM on admission 8,570 (11.0) 82 (25.4) <0.0001
Albumin <= 2.4 g/dL 2,123 (2.7) 36 (11.1)
<0.0001Albumin 2.5 - 2.7 g/dL 1,822 (2.3) 30 (9.3)
Albumin 2.8 - 3 g/dL 3,126 (4.0) 39 (12.1)
Albumin <= 3 g/dL 7,071 (9.1) 105 (32.5) <0.0001
Creatinine > 2.0 mg/dL 6,280 (8.1) 72 (22.3) <0.0001
Pro BNP > 8000 104 (0.1) 4 (1.2) <0.0001
Bands > 32% 886 (1.1) 16 (5.0) <0.0001
Platelets <= 115 10^9/L 5,590 (7.2) 44 (13.6)
<0.0001Platelets 115.1 - 150 10^9/L 5,539 (7.1) 41 (12.7)
Platelets > 420 10^9/L 3,191 (4.1) 27 (8.4)
Platelets <=150 or >420 10^9/L 14,320 (18.4) 112 (34.7) <0.0001
WBC 11 - 14.1 ×1,000/mm3 12,010 (15.4) 72 (22.3)
<0.0001WBC 14.2 - 19.8 ×1,000/mm3 8,169 (10.5) 59 (18.3)
WBC 1>19.8 ×1,000/mm3 4,092 (5.3) 36 (11.1)
WBC > 11 ×1,000mm3 24,271 (31.2) 167 (51.7) <0.0001
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Variable Non-Cases, n (Column %)
HO-CDI Cases, n 
(Column %) Univariate P-Value
Troponin I >0.1 or CPK MB >=6 ng/mL 6,863 (8.8) 54 (16.7) <0.0001
Community-Onset CDI Pressure, per 10,000 admissions, 
median (1st, 3rd quartile) 19.3 (0, 38.9) 20.9 (0, 41.6) 0.2551
All Community-Onset CDI Pressure, per 10,000 admissions, 
median (1st, 3rd quartile) 52.7 (27.4, 85.7) 59.5 (30.7, 94.0) 0.0499
Note: NIM: nosocomial infection marker; CIM: community infection marker; WBC: white blood cell count
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